Skip to main content
. 2023 Feb 2;64(3):100339. doi: 10.1016/j.jlr.2023.100339

Fig. 3.

Fig. 3

The effect of either low or high dose of fenofibrate in combination with ACCi on LDL-apoB FRR and ASR in NASH patients. A: LDL-apoB FRR (mean values ± SEM) for ACCi alone in both noncirrhotic and cirrhotic subjects versus, ACCi + two combined fenofibrate (48 mg/day and 145 mg/day) doses were 46 ± 6 and 33 ± 4%/day, respectively. ACCi+fenofibrate lowered LDL-apoB FRR than the ACCi treated group alone, P = 0.032. B: LDL-apoB ASR (mean values ± SEM) for ACCi alone in both noncirrhotic and cirrhotic subjects versus, ACCi + two combined fenofibrate (48 mg/day and 145 mg/day) doses were 45 ± 4 and 34 ± 4 mg/dl/day, respectively. ACCi+fenofibrate lowered LDL-apoB ASR to near baseline levels than the ACCi treated group alone, P = 0.026. C: Change in LDL-apoB FRR ± SEM from baseline to ACCi treatment in NASH subjects with both noncirrhosis and cirrhosis, and from baseline to ACCi + two combined fibrate doses (48 mg+145 mg) were 15 ± 6 and −2 ± 5%/day (P = 0.028), respectively. D: Change in LDL-apoB ASR ± SEM from baseline to ACCi treatment in NASH subjects with both noncirrhosis and cirrhosis, and from baseline to ACCi + two combined fibrate doses (48 mg+145 mg) were 15 ± 5 and 3 ± 4 mg/dl/day (P = 0.04), respectively. Data are expressed as mean ± SEM. Statistical significance was evaluated by one-tailed unpaired t test, ∗P ≤ 0.05. ACCi, acetyl-CoA carboxylase inhibitor; ASR, absolute synthesis rate; FRR, fractional replacement rate; NASH, nonalcoholic steatohepatitis.